Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

SAB Biotherapeutics (SABS) Return on Assets (2021 - 2025)

Historic Return on Assets for SAB Biotherapeutics (SABS) over the last 5 years, with Q3 2025 value amounting to 0.4%.

  • SAB Biotherapeutics' Return on Assets rose 3900.0% to 0.4% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.4%, marking a year-over-year increase of 3900.0%. This contributed to the annual value of 0.65% for FY2024, which is 300.0% down from last year.
  • SAB Biotherapeutics' Return on Assets amounted to 0.4% in Q3 2025, which was up 3900.0% from 1.2% recorded in Q2 2025.
  • SAB Biotherapeutics' Return on Assets' 5-year high stood at 0.05% during Q3 2021, with a 5-year trough of 1.2% in Q2 2025.
  • In the last 5 years, SAB Biotherapeutics' Return on Assets had a median value of 0.58% in 2023 and averaged 0.56%.
  • Examining YoY changes over the last 5 years, SAB Biotherapeutics' Return on Assets showed a top increase of 3900bps in 2025 and a maximum decrease of -5900bps in 2025.
  • SAB Biotherapeutics' Return on Assets (Quarter) stood at 0.17% in 2021, then plummeted by -109bps to 0.36% in 2022, then crashed by -108bps to 0.75% in 2023, then increased by 11bps to 0.67% in 2024, then skyrocketed by 40bps to 0.4% in 2025.
  • Its last three reported values are 0.4% in Q3 2025, 1.2% for Q2 2025, and 0.93% during Q1 2025.